Globus Medical - GMED Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $77.36
  • Forecasted Upside: 26.78 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.45 (2.43%)

This chart shows the closing price for GMED by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Globus Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMED

Analyst Price Target is $77.36
▲ +26.78% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Globus Medical in the last 3 months. The average price target is $77.36, with a high forecast of $100.00 and a low forecast of $62.00. The average price target represents a 26.78% upside from the last price of $61.02.

This chart shows the closing price for GMED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Globus Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022BTIG ResearchLower Target$71.00N/A
8/5/2022Piper SandlerLower TargetOverweight$80.00 ➝ $75.00Low
7/20/2022Truist FinancialLower TargetBuy$76.00 ➝ $71.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$68.00 ➝ $62.00Low
6/3/2022Piper SandlerLower Target$80.00Low
5/11/2022Canaccord Genuity GroupLower Target$80.00 ➝ $75.00High
5/11/2022Wells Fargo & CompanyLower Target$80.00 ➝ $70.00High
3/28/2022Wells Fargo & CompanyInitiated CoverageOverweight$80.00High
2/22/2022Morgan StanleyLower TargetEqual Weight$82.00 ➝ $74.00Medium
2/18/2022Credit Suisse GroupLower TargetOutperform$95.00 ➝ $91.00High
2/18/2022Needham & Company LLCLower TargetBuy$92.00 ➝ $76.00High
1/7/2022Morgan StanleyBoost TargetEqual Weight$80.00 ➝ $82.00Low
1/4/2022Piper SandlerUpgradeNeutral ➝ Overweight$80.00 ➝ $88.00High
12/13/2021Bank of AmericaUpgradeUnderperform ➝ Buy$55.00 ➝ $80.00High
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$80.00Low
11/5/2021Piper SandlerLower TargetNeutral ➝ Neutral$85.00 ➝ $80.00High
10/28/2021Loop CapitalInitiated CoverageBuy$100.00Medium
8/5/2021Morgan StanleyBoost TargetEqual Weight$77.00 ➝ $80.00Medium
8/5/2021SVB LeerinkBoost TargetOutperform$88.00 ➝ $96.00High
8/5/2021Credit Suisse GroupBoost TargetOutperform$86.00 ➝ $91.00High
8/5/2021Wells Fargo & CompanyBoost TargetOverweight$78.00 ➝ $90.00High
8/5/2021Needham & Company LLCBoost TargetBuy$82.00 ➝ $92.00Medium
8/5/2021CitigroupBoost TargetBuy$81.00 ➝ $93.00Medium
5/5/2021CitigroupBoost Target$77.00 ➝ $81.00High
5/5/2021BTIG ResearchBoost TargetBuy$72.00 ➝ $81.00High
5/5/2021Morgan StanleyBoost TargetEqual Weight$72.00 ➝ $77.00High
5/5/2021Wells Fargo & CompanyBoost TargetOverweight$71.00 ➝ $78.00High
5/5/2021SVB LeerinkBoost TargetOutperform$74.00 ➝ $81.00High
5/5/2021Needham & Company LLCBoost TargetBuy$75.00 ➝ $82.00High
2/25/2021Morgan StanleyBoost TargetEqual Weight$69.00 ➝ $72.00Medium
2/18/2021CitigroupBoost Target$72.00 ➝ $77.00Medium
2/18/2021Needham & Company LLCBoost TargetBuy$65.00 ➝ $75.00Medium
2/18/2021BTIG ResearchBoost TargetBuy$63.00 ➝ $72.00High
1/29/2021Piper SandlerBoost TargetNeutral$55.00 ➝ $63.00High
1/8/2021Credit Suisse GroupBoost TargetTop Pick ➝ Outperform$64.00 ➝ $75.00Low
12/15/2020Morgan StanleyBoost TargetEqual Weight$58.00 ➝ $69.00Medium
12/8/2020Smith Barney CitigroupInitiated CoverageBuy$72.00Low
10/29/2020Credit Suisse GroupBoost TargetOutperform$58.00 ➝ $64.00High
10/19/2020Stifel NicolausInitiated CoverageHold$56.00Medium
8/6/2020OppenheimerInitiated CoverageHold$56.00Medium
8/6/2020Piper SandlerBoost TargetNeutral$50.00 ➝ $55.00Low
8/6/2020Wells Fargo & CompanyBoost TargetOverweight$54.00 ➝ $56.00Low
8/6/2020Credit Suisse GroupBoost TargetOutperform$57.00 ➝ $58.00High
8/6/2020Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $58.00High
8/6/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$65.00High
8/6/2020SVB LeerinkBoost TargetOutperform$56.00 ➝ $64.00High
8/6/2020Needham & Company LLCBoost TargetBuy$60.00 ➝ $65.00High
7/21/2020Northland SecuritiesInitiated CoverageMarket Perform$50.00Low
7/6/2020Piper SandlerDowngradeOverweight ➝ Neutral$60.00 ➝ $50.00High
5/8/2020UBS GroupLower TargetBuy$67.00 ➝ $61.00Medium
5/8/2020Credit Suisse GroupBoost TargetOutperform$56.00 ➝ $57.00Low
5/8/2020Morgan StanleyBoost TargetEqual Weight$48.00 ➝ $52.00High
5/8/2020SVB LeerinkLower TargetOutperform$63.00 ➝ $56.00High
5/8/2020Needham & Company LLCLower TargetBuy$63.00 ➝ $60.00High
5/8/2020BTIG ResearchReiterated RatingBuy$53.00High
4/6/2020Wells Fargo & CompanyLower TargetOverweight$63.00 ➝ $50.00Low
3/27/2020Morgan StanleyLower TargetEqual Weight$60.00 ➝ $48.00Medium
3/18/2020BTIG ResearchUpgradeNeutral ➝ Buy$46.00High
3/6/2020Credit Suisse GroupLower TargetOutperform$67.00 ➝ $59.00Medium
2/24/2020Credit Suisse GroupReiterated RatingBuy$67.00High
1/9/2020Cantor FitzgeraldReiterated RatingBuy$64.00High
1/8/2020Credit Suisse GroupBoost TargetOutperform$59.00 ➝ $67.00Low
1/7/2020SunTrust BanksInitiated CoverageBuy$67.00Low
1/2/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
12/18/2019UBS GroupBoost TargetBuy$61.00 ➝ $67.00Low
12/17/2019Morgan StanleyBoost TargetEqual Weight$57.00 ➝ $60.00Low
12/12/2019Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$63.00Low
11/7/2019BTIG ResearchReiterated RatingHoldLow
11/7/2019Needham & Company LLCReiterated RatingBuy$63.00High
11/7/2019Cantor FitzgeraldBoost TargetOverweight$55.00 ➝ $64.00High
10/8/2019Wells Fargo & CompanyBoost TargetMarket Perform$42.00 ➝ $53.00High
8/2/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $56.00High
6/5/2019Morgan StanleySet TargetHold$45.00Low
5/24/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$50.00 ➝ $41.00Low
5/3/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$57.00 ➝ $52.00High
3/19/2019OppenheimerReiterated RatingHoldLow
3/1/2019Cantor FitzgeraldReiterated RatingBuy$60.00Low
2/28/2019UBS GroupUpgradeNeutral ➝ Buy$55.00High
1/18/2019Cantor FitzgeraldSet TargetBuy$60.00Low
1/9/2019Cantor FitzgeraldReiterated RatingBuy$65.00High
1/2/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$64.00 ➝ $49.00High
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$53.00Medium
11/28/2018UBS GroupInitiated CoverageNeutral$55.00High
11/13/2018Cantor FitzgeraldSet TargetBuy$65.00Low
11/9/2018SVB LeerinkBoost TargetOutperform$61.00 ➝ $65.00Low
11/9/2018Piper Jaffray CompaniesBoost TargetOverweight$62.00Low
11/9/2018OppenheimerSet TargetHold$61.00High
9/25/2018Morgan StanleyBoost TargetOverweight ➝ Buy$60.00 ➝ $64.00Medium
8/2/2018OppenheimerSet TargetHold$57.00Medium
8/2/2018Needham & Company LLCBoost TargetBuy$58.00 ➝ $65.00Medium
8/2/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$58.00 ➝ $60.00High
6/27/2018Bank of AmericaDowngradeNeutral ➝ Underperform$55.00High
5/31/2018Cantor FitzgeraldInitiated CoverageOverweight$65.00Low
5/30/2018SVB LeerinkBoost TargetOutperform ➝ Outperform$60.00 ➝ $61.00Medium
5/3/2018OppenheimerSet TargetHold$52.00Low
5/3/2018Morgan StanleyBoost TargetOverweight ➝ Buy$53.00 ➝ $58.00Low
5/3/2018Needham & Company LLCBoost TargetBuy ➝ Buy$57.00 ➝ $58.00High
4/16/2018BTIG ResearchReiterated RatingBuy ➝ Neutral$37.00Low
4/4/2018Needham & Company LLCUpgradeHold ➝ Buy$57.00Medium
3/28/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$56.00 ➝ $60.00Low
2/22/2018OppenheimerSet TargetHold$49.00Medium
2/22/2018Morgan StanleySet TargetOverweight ➝ Buy$48.00 ➝ $53.00Medium
2/22/2018Needham & Company LLCReiterated RatingHoldMedium
2/22/2018BTIG ResearchBoost TargetOutperform ➝ Buy$51.00Medium
1/10/2018BarclaysReiterated RatingSell$36.00Medium
1/10/2018Wells Fargo & CompanyReiterated RatingOutperform$46.00 ➝ $51.00High
1/2/2018BTIG ResearchSet TargetBuy$45.00High
1/2/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$48.00High
12/4/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$46.00High
11/20/2017BTIG ResearchSet TargetBuy$42.00N/A
11/14/2017GabelliReiterated RatingBuyN/A
11/10/2017Bank of AmericaUpgradeUnderperform ➝ NeutralN/A
11/9/2017BarclaysBoost TargetUnderweight$27.00 ➝ $29.00N/A
11/9/2017Needham & Company LLCReiterated RatingHoldN/A
11/9/2017BTIG ResearchReiterated RatingBuy$37.00N/A
10/19/2017Piper Jaffray CompaniesReiterated RatingBuyN/A
10/19/2017BarclaysLower TargetUnderweight$28.00 ➝ $27.00N/A
(Data available from 10/3/2017 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.


  • No negative mentions tracked during this time.
Globus Medical logo
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Read More

Today's Range

Now: $61.02
Low: $59.28
High: $61.21

50 Day Range

MA: $61.12
Low: $57.74
High: $67.54

52 Week Range

Now: $61.02
Low: $52.60
High: $81.78


5,874 shs

Average Volume

683,268 shs

Market Capitalization

$6.07 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Globus Medical?

The following Wall Street research analysts have issued reports on Globus Medical in the last year: Bank of America Co., BTIG Research, Canaccord Genuity Group Inc., Credit Suisse Group AG, Loop Capital, Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank of Canada,, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for GMED.

What is the current price target for Globus Medical?

11 Wall Street analysts have set twelve-month price targets for Globus Medical in the last year. Their average twelve-month price target is $77.36, suggesting a possible upside of 26.8%. Loop Capital has the highest price target set, predicting GMED will reach $100.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $62.00 for Globus Medical in the next year.
View the latest price targets for GMED.

What is the current consensus analyst rating for Globus Medical?

Globus Medical currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GMED will outperform the market and that investors should add to their positions of Globus Medical.
View the latest ratings for GMED.

What other companies compete with Globus Medical?

Other companies that are similar to Globus Medical include Integra LifeSciences, NuVasive, Teleflex, AtriCure and Abiomed. Learn More about companies similar to Globus Medical.

How do I contact Globus Medical's investor relations team?

Globus Medical's physical mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company's listed phone number is (610) 930-1800 and its investor relations email address is [email protected] The official website for Globus Medical is Learn More about contacing Globus Medical investor relations.